Literature DB >> 3872738

Prevention of congenital rubella in Iceland by antibody screening and immunization of seronegative females.

S Gudmundsdóttir, A Antonsdóttir, S Gudnadóttir, S Elefsen, B Einarsdóttir, O Olafsson, M Gudnadóttir.   

Abstract

A programme to eradicate congenital rubella from Iceland was started in 1979, based on (1) screening of all females aged 12-45 years for rubella antibodies and (2) vaccination of all seronegative persons with the RA/27/3 rubella vaccine, given free of charge. Thus, individual protection was offered to all who needed it. The collection of serum samples was planned to last for 2 years while, simultaneously, the already established rubella screening and immunization programmes for 12-year-old schoolgirls and pregnant women continued.During assessment in 1983, 95.2% of females in the first 7 age groups (by now aged 14-20 years) participating in the school programme had been tested and 80.4% of them were found to be naturally immune. Of the seronegatives, 93.7% were subsequently vaccinated, thus giving an overall immunity rate of 98.8%. Among the women in the peak of the childbearing period (by now aged 21-35 years), 84.4% had been tested and 92.7% were found to be naturally immune; vaccination of 61.4% of seronegative individuals then gave an overall immunity rate of 97.2% for this age group.If it is assumed that the natural immunity rate of females still untested is like that of the above groups, then the percentage of non-immune persons is at present 2.1% in the younger group and 3.4% in the older.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3872738      PMCID: PMC2536347     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  14 in total

1.  Hemolysis-in-gel test for the demonstration of antibodies to rubella virus.

Authors:  O Strannegård; L Grillner; I M Lindberg
Journal:  J Clin Microbiol       Date:  1975-06       Impact factor: 5.948

2.  A comparison of three tests for rubella antibody screening.

Authors:  P Morgan-Capner; H J Pullen; J R Pattison; D E Bidwell; A Bartlett; A Voller
Journal:  J Clin Pathol       Date:  1979-06       Impact factor: 3.411

Review 3.  A nation-wide epidemic of rubella in Japan during the three year period 1975--1977.

Authors:  A Shishido; M Hirayama; M Kimura
Journal:  Jpn J Med Sci Biol       Date:  1979-10

4.  The epidemiology of rubella on Taiwan. II. 1968-1969 epidemic.

Authors:  J L Gale; J T Grayston; R P Beasley; R Detels; K S Kim
Journal:  Int J Epidemiol       Date:  1972       Impact factor: 7.196

5.  Rubella hemagglutinin prepared with alkaline extraction of virus grown in suspension culture of BHK-21 cells.

Authors:  P E Halonen; J M Ryan; J A Stewart
Journal:  Proc Soc Exp Biol Med       Date:  1967-05

6.  Rubella in Iceland.

Authors:  H O Tómasson; H M Ogmundsdóttir
Journal:  Acta Pathol Microbiol Scand B       Date:  1975-06

7.  The derivation of a minimum immune titre of rubella haemagglutination-inhibition (HI) antibody. A Public Health Laboratory Service collaborative survey.

Authors:  C M Bradstreet; B Kirkwood; J R Pattison; J O Tobin
Journal:  J Hyg (Lond)       Date:  1978-12

8.  Vaccination against rubella in Britain: benefits and risks.

Authors:  D S Freestone
Journal:  Dev Biol Stand       Date:  1979

9.  Strategy for rubella vaccination.

Authors:  E G Knox
Journal:  Int J Epidemiol       Date:  1980-03       Impact factor: 7.196

10.  WHO collaborative study on the sero-epidemiology of rubella.

Authors:  W E Rawls; J L Melnick; C M Bradstreet; M Bailey; A A Ferris; N I Lehmann; F P Nagler; J Furesz; R Kono; M Ohtawara; P Halonen; J Stewart; J M Ryan; J Strauss; J Zdrazilek; J Leerhoy; H Von Magnus; R Sohier; W Ferreira
Journal:  Bull World Health Organ       Date:  1967       Impact factor: 9.408

View more
  1 in total

Review 1.  Rubella vaccination.

Authors:  J Forster
Journal:  Eur J Pediatr       Date:  1988-08       Impact factor: 3.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.